Core Viewpoint - Chao Yan Co., Ltd. has shown a positive performance in stock trading and financial results, indicating growth potential in the medical imaging and industrial non-destructive testing equipment sectors [1][2]. Financial Performance - As of June 30, 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, representing a year-on-year growth of 15% [2]. - The net profit attributable to shareholders for the same period was approximately 68.45 million yuan, reflecting an 18.5% increase compared to the previous year [2]. Stock Trading Activity - On October 14, 2023, Chao Yan Co., Ltd. saw a stock price increase of 2.24%, with a trading volume of approximately 92.23 million yuan [1]. - The financing buy-in amount for the same day was 6.48 million yuan, while the financing repayment was 6.92 million yuan, resulting in a net financing buy-in of -0.43 million yuan [1]. - The total financing and securities balance as of October 14, 2023, was approximately 95.63 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares per shareholder increased by 19.98% to 2,456 shares [2]. Dividend Distribution - Chao Yan Co., Ltd. has distributed a total of 43.69 million yuan in dividends since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [3]. - Other notable institutional shareholders include Southern Zhongzheng 1000 ETF and Hong Kong Central Clearing Limited, with significant shareholdings and increases [3].
超研股份10月14日获融资买入648.16万元，融资余额9541.87万元